There was no significant difference in tumour cellularity and TP53 allele fraction between UMFIX and NBF samples, thus allowing a direct comparison of DNA metrics (supplementary Figure S1, available at Annals of Oncology online). This evidence concerns the gene TP53 and neoplasm.